Pfizer Inc | StockChase
615
Pfizer Inc (PFE-N)

Last Price Recorded: $35.3700 on 2017-11-17

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Pfizer Inc


Signal Opinion Expert

2017-11-13

BUY
Pfizer Inc (PFE-N)

One of the great American pharmaceutical stocks. A little cheaper than a lot of them. They don’t have a whole series of blockbusters hitting the lights out, but have a very diverse product line. They’ve made some acquisitions and will make more. Extremely well-managed. Believes it can drift towards the low $40. A good solid Buy and Hold. Dividend yield of 3.6%.

biotechnology/pharmaceutical
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $35.300
Owned: Yes

2017-10-26

BUY
Pfizer Inc (PFE-N)

A Pharma US stock with dividends and growth.  PFE-T is the one he would recommend.  It is a very well run company with a steady dividend and a good pipeline of new drugs.  It has pretty good shareholder friendly management that buy back stock and create value.  It is his favourite way to participate in aging demographics.

biotechnology/pharmaceutical
Colin Stewart

CEO & Portfolio manager, JC Clark Investments Ltd.

Price: $35.740
Owned: Unknown

2017-10-23

COMMENT
Pfizer Inc (PFE-N)

In the 90s, drug companies traded at 30X earnings with 10% earnings growth. All the drug companies are suffering badly because they are not getting a good return on R&D. Every country is putting pressure on pharmaceutical prices. This is trading at 20X earnings and has lots of free cash flow, but the drug sector is simply a very difficult place to be.

biotechnology/pharmaceutical
Lorne Steinberg

President & Portfolio Manager, Lorne Steinberg Wealth Management Inc

Price: $36.400
Owned: Unknown

2017-10-17

COMMENT
Pfizer Inc (PFE-N)

Has owned this for a long time. Rates of return over the last 5 or 6 years have been mediocre. Trading at $36, and his model price is $45.72, a 27% upside. Pays a 3.56% dividend. They have been totally incompetent. If rates of return ever kept up with the rest of the drug space, he would buy it here and hold it, but it is a frustrating stock.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $36.200
Owned: Yes

2017-09-22

COMMENT
Pfizer Inc (PFE-N)

The trouble with these kind of drug companies is that they made lots of acquisitions, which is how they have grown. Many were considered growth companies because they came out with social drugs, and ended up with huge multiples. There are lots of good things in their pipeline, but there are not going to be these massive, massive blockbuster drugs they used to have.

biotechnology/pharmaceutical
Paul Harris, CFA

Portfolio Manager and Partner, Avenue Investment Management

Price: $35.960
Owned: No

2017-09-20

COMMENT
Pfizer Inc (PFE-N)

(Market Call Minute.) This has run up a little bit lately. He likes to buy this at $31 and sell it at $38.

biotechnology/pharmaceutical
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $35.990
Owned: Unknown

2017-09-14

BUY
Pfizer Inc (PFE-N)

They have a ability to be a global commercialization machine.  They have 125 drugs that generate in excess of $100 million in revenue.  It is on the uptick after passing the patent cliff.  It does have a whole lot of pipeline excitement over the next couple of quarters, but it has a 12.9 times forward earnings with a 3.9% dividend yield. 

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $35.730
Owned: Yes

2017-09-07

COMMENT
Pfizer Inc (PFE-N)

All the Pharma companies are in a really tough space. Every government globally is squeezing them on prices. They have less and less money to spend on R&D, which means they are having trouble coming up with new blockbuster drugs. The FDA and everyone else are pushing generics as fast as possible. These companies really haven’t had huge blockbusters. He is not a big fan in general of the Pharma sector.

biotechnology/pharmaceutical
Lorne Steinberg

President & Portfolio Manager, Lorne Steinberg Wealth Management Inc

Price: $33.990
Owned: Unknown

2017-09-05

PAST TOP PICK
Pfizer Inc (PFE-N)

(A Top Pick June 9/17. Up 4.29%.) Arguably your best pharmaceutical company in the world, with the largest research and development pipeline and the largest salesforce. It is not just domestically focused, but has tremendous operations overseas internationally, including emerging markets. Has a nice, juicy 4% dividend yield.

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Management

Price: $33.800
Owned: Yes

2017-09-05

TOP PICK
Pfizer Inc (PFE-N)

The 5th largest dividend payer in the Dow at about 3.9%. It is world-class because it is the largest in what they do, international operations with less risk. A conservative way to be a contrarian in the health care space, despite all the wrangling in Washington. Dividend yield of 3.7%. (Analysts’ price target is $37.)

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Management

Price: $33.800
Owned: Yes

2017-09-01

COMMENT
Pfizer Inc (PFE-N)

This is a company where earnings forecasts have basically flat lined for about 10 years. Therefore, his FMV calculation has also flatlined and hasn’t really gone anywhere. When those things happen to stocks, the market says “forget about it”, and tend to sell off, which could give you some good opportunities to buy. They will then take a little run and fluctuate up and down around the FMV calculation. This stock is about there now, kind of at the midpoint of its valuation. The highs and lows are $27 and $38, and the stock is threading the needle. If it fell back to $27-$28, he would love to buy some for a trade. If it went to $38, he would sell it Short. This is not a “Buy and Hold” strategy, because earnings haven’t gone anywhere for 10 years, which also means the BV hasn’t gone anywhere. You want to start where the balance sheet is rising steadily, so that if you are standing still, the values are rising underneath you. However, if the values are not rising, and the balance sheet is flat lining, you are not getting richer just by standing still.

biotechnology/pharmaceutical
Ross Healy

Chairman, Strategic Analysis Corp

Price: $33.960
Owned: Unknown

2017-08-10

COMMENT
Pfizer Inc (PFE-N)

Big pharmas have struggled with their drug pipeline coming off patents, and how to replace them. This one has struggled with their organic growth rate, and has been relying a lot on acquisitions. Investors don’t like that as a sustainable approach. However, now they have some things in the development pipeline that look pretty promising, with some thought that they can generate 2%-3% top line growth from those. This is positive and can maybe re-rate the shares higher. It seems like a pretty attractive valuation at this point. She has played the drug theme through Quintiles IMS Holdings (Q-N).

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment Management

Price: $33.420
Owned: No

2017-08-01

COMMENT
Pfizer Inc (PFE-N)

Not a high-risk story. They are one of the largest drug companies with a lot of drugs, and are able to cut costs and move things around. Dividend yield of around 3.9%. Thinks it goes back into the low $40s. You are buying a company that has all of the assets, and they just need the assets to start working, which at some point in time they will.

biotechnology/pharmaceutical
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $33.080
Owned: Yes

2017-07-25

HOLD
Pfizer Inc (PFE-N)

It is one of the two drug stocks he owns.  It has not done a lot in the last couple of years.  It made acquisitions in order to get over its patent cliff.  He thinks sooner than later it will break out of its sideways trading.

biotechnology/pharmaceutical
Norman Levine

Managing Director, Portfolio Management Corp

Price: $33.100
Owned: Yes

2017-07-20

PAST TOP PICK
Pfizer Inc (PFE-N)

(A Top Pick May 26/16. Up 1.19%.) This is going to have a bit more of a headwind because Viagra is coming off patent next week. This is a really good space, and it has a seasonality that kicks in, in June. There are probably stronger names than Pfizer.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $33.540
Owned: No

Showing 1 to 15 of 615 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.